Drug intelligence / Profile preview

SRNDO-01

Development stage: Preclinical
Lead developer: Sirius Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SRNDO-01 is a preclinical small interfering RNA (siRNA) therapeutic candidate being developed by Sirius Therapeutics (formerly Sirius Natural) for the treatment of obesity. The drug utilizes siRNA-mediated gene silencing to modulate an undisclosed molecular target involved in metabolic regulation and weight management. SRNDO-01 is designed to leverage the company's proprietary delivery platforms, which enable targeted delivery to specific tissues including the liver, adipose tissue, heart, kidney, or central nervous system (CNS). It is currently in the pre-clinical/IND-enabling stage of development.

Other names: Sirius Natural

Targets

F11 (Coagulation Factor XI)

Beyond the preview

Go deeper on SRNDO-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRNDO-01.

Explore the full profile